Target Corporation (TGT)
Nutex Health: The Stock Has Had A Great Run, But New Guidance Justifies A Higher Target Price (Rating Upgrade)
Nutex Health is rated Strong Buy, with a new target price of $290.43, representing 39.1% upside from current levels. NUTX's profitability and growth metrics significantly outpace peers, driven by effective use of the No Surprises Act and disciplined cost controls. Consensus EPS projections for FY2026 and FY2027 have materially increased, with FY2026 EPS now expected at $27.79, supporting a forward PE of just 10.5.
A $2,400 Price Target on SanDisk Just Lit a Fire Under Every Memory Stock
One analyst's initiation on SanDisk sent shockwaves through every memory stock at once, and the reason why suggests this may be a very different kind of NAND cycle than anything the market has seen before.
Micron Price Target Raised to $1,300 by Citi on Stronger DRAM Pricing, Undersupply
Citi just lifted its Micron price target, but here is the catch: even that higher number sits well below what Wall Street analysts collectively expect, raising the question of how much further this rally has left to run.
Micron Wall Street Target Hits $2,000 as Traders Pile In Before Earnings
Wall Street analysts are fighting over Micron more violently than they have in years, with targets ranging from a humble hold to a stunning $2,000 price, and a single line in the September 30 earnings report will determine who looks
Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress
Arrowhead Pharmaceuticals NASDAQ: ARWR executives outlined early clinical data for its RNA interference dimer program, progress in the launch of plozasiran and plans for central nervous system and metabolic disease candidates during the Morgan Stanley Global Healthcare Conference. Get ARWR alerts:Sign UpEarly Dimer Data Points to Dual-Target Approach Chief Executive Officer Chris Anzalone said the company's ARO-DIMER-PA candidate represented the first demonstration of knockdown of two genes with a single RNAi molecule.
TGT vs. COST: Which Stock Should Value Investors Buy Now?
Investors interested in Retail - Discount Stores stocks are likely familiar with Target (TGT) and Costco (COST). But which of these two companies is the best option for those looking for undervalued stocks?
Target (TGT) Up 1% Since Last Earnings Report: Can It Continue?
Target (TGT) reported earnings 30 days ago. What's next for the stock?
Downgrade, Steep Price-Target Cut Dings Netflix Stock
Shares of Netflix (NASDAQ:NFLX) have dropped 4.8% to trade at $71.72 this morning, after Wells Fargo downgraded the streamer to "underweight" and readjusted their price target to $57 from $80.
Is Trending Stock Target Corporation (TGT) a Buy Now?
Zacks.com users have recently been watching Target (TGT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Target Stock Up More Than 30% in 6 Months: Is It Too Late to Buy TGT?
Target's 34.4% six-month rally is backed by stronger traffic, digital momentum and higher-margin growth, but its valuation now tops its one-year median.
Silicon Motion: I'm Raising My Price Target As Enterprise Growth Accelerates
I maintain a Strong Buy on Silicon Motion Technology with a revised $409 price target, reflecting accelerated enterprise and AI storage growth. Ferri and Enterprise Boot Drive solutions now contribute nearly 30% of revenue, up from 4% a year ago, materially strengthening my thesis. While PCIe Gen5 adoption is slower than expected, this is offset by rapid scaling in MonTitan, Ferri, and enterprise boot drives, driving my 2027 EPS estimate to $15.13.
Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
Believe it or not, the holiday shopping season is here, so it's time to consider the best plays. As it stands, seasonal sales growth is expected to accelerate year over year to 4.55% to 4.8%, topping $1.7 trillion for the first time, underpinned as always by e-commerce.
